AEON Biopharma (AEON) Proxy Filing summary

Executive summary

• Special Meeting called to approve key financing and capital structure proposals to fund ABP-450 biosimilar development and commercialization efforts, including a PIPE financing, convertible note exchange, and equity plan amendment.

• Company is pursuing a Section 351(k) biosimilar regulatory pathway for ABP-450, shifting from prior clinical programs after Phase 2 migraine trials did not meet endpoints.

• As of September 30, 2025, cash and cash equivalents were $5.9 million, with an accumulated deficit of $433.7 million; management has concluded there is substantial doubt about the ability to continue as a going concern without additional funding.

• Recent financings include a $15 million convertible note from Daewoong, a $18.3 million public offering, and a $6 million PIPE, with further closings subject to shareholder approval.

• NYSE American has granted the company until August 3, 2026, to regain compliance with minimum stockholders' equity requirements.

Voting matters and shareholder proposals

• Four proposals: (1) PIPE Financing Proposal for issuance of shares and warrants, (2) Exchange Proposal for convertible note exchange with Daewoong, (3) Equity Plan Proposal to increase shares under the incentive plan, (4) Adjournment Proposal to solicit additional proxies if needed.

• Board recommends voting FOR all proposals; PIPE and Exchange Proposals are interdependent and require mutual approval.

• Shareholders of record as of December 15, 2025, are eligible to vote; quorum is 33.34% of voting power.

Board of directors and corporate governance

• Board composition includes a Daewoong designee as Class III director; recent CEO transition with Robert Bancroft appointed in April 2025.

• Board and committees oversee compensation, audit, and governance; director compensation includes cash retainers and equity awards.

• Board has adopted a clawback policy for executive compensation in line with SEC and NYSE rules.